Other Malaria work


MVI Path Initiative: Collaboration with the Jenner Institute, Oxford University, UK

BE_logo_23BE_logo_5

A collaboration with the team involved in transmission-blocking vaccine approaches to malaria was awarded funding by the MVI PATH for “Production of recombinant malaria transmission-blocking vaccine antigens in Drosophila S2 insect stable cell lines using the ExpreS2 system”.

Related links:

http://www.jenner.ac.uk/malaria
http://www.jenner.ac.uk/malaria-programme-transmission-blocking-vaccines

Global immunology: Collaboration with Statens Serum Institute, DK

BE_logo_10 BE_logo_8

To date, virtually all attempts to develop a vaccine against malaria have been based on patients, parasites and mosquitoes from Africa, where the disease is most prevalent. But the disease also occurs in Southeast Asia, and now money from the Strategic Research has been allocated to investigate whether the disease has different traits in India.

WHO estimates that approximately 24 million Indians are annually infected with malaria. But how will a vaccine developed against the parasite in Africa, perform in a different geography? Funding from the Danish Council for Strategic Research will be used in a research project to investigate whether there are differences in how malaria develops in Africans and Indians.

The collaboration involves the SSI, Copenhagen University and ExpreS2ion Biotechnologies, in Denmark, and several Indian research Institutes. The antibody profiles in these samples will be assessed in a variety of functionality tests to give indications of whether the Indian malaria patients in general will benefit from the Danish vaccine candidates, or whether new vaccine candidates need to be defined for a effective vaccine in India.

Related links:

http://www.ssi.dk/Aktuelt/Forskningsnyt/2013